RegeneRx Biopharmaceuticals Inc. (“RegeneRx” or the “Company”) (OTCQB:RGRX) is a biopharmaceutical company focused on the development of a novel therapeutic peptide, Thymosin beta 4, or Tß4, for tissue and organ protection, repair, and regeneration. We have formulated Tß4 into three distinct product candidates in clinical development:
Company profile
Ticker
RGRX
Exchange
Website
CEO
J. J. Finkelstein
Employees
Incorporated
Location
Fiscal year end
Sector
Industry (SIC)
Former names
ALPHA 1 BIOMEDICALS INC, ALPHA 1 BIOMEDICALS INC /DE/
SEC CIK
Corporate docs
IRS number
521253406
RGRX stock data
Latest filings (excl ownership)
10-Q
2022 Q3
Quarterly report
14 Nov 22
10-Q
2022 Q2
Quarterly report
12 Aug 22
10-Q
2022 Q1
Quarterly report
16 May 22
10-K
2021 FY
Annual report
30 Mar 22
424B3
Prospectus supplement
17 Nov 21
10-Q
2021 Q3
Quarterly report
15 Nov 21
8-K
2021 Annual Stockholders Meeting
15 Nov 21
DEFR14A
Revised proxy
19 Oct 21
DEF 14A
Definitive proxy
18 Oct 21
PRE 14A
Preliminary proxy
8 Oct 21
Financial summary
| Quarter (USD) | Sep 22 | Jun 22 | Mar 22 | Dec 21 | |
|---|---|---|---|---|---|
| Revenue | |||||
| Cost of revenue | |||||
| Operating income | |||||
| Operating margin | |||||
| Net income | |||||
| Net profit margin | |||||
| Cash on hand | |||||
| Change in cash | |||||
| Diluted EPS |
| Annual (USD) | Dec 21 | Dec 20 | Dec 19 | Dec 18 | |
|---|---|---|---|---|---|
| Revenue | |||||
| Cost of revenue | |||||
| Operating income | |||||
| Operating margin | |||||
| Net income | |||||
| Net profit margin | |||||
| Cash on hand | |||||
| Change in cash | |||||
| Diluted EPS |
| Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
|---|---|---|---|---|---|---|
| Cash on hand (at last report) | 478.41 k | 478.41 k | 478.41 k | 478.41 k | 478.41 k | 478.41 k |
| Cash burn (monthly) | 76.08 k | 87.08 k | 122.17 k | 148.84 k | 76.08 k | 87.08 k |
| Cash used (since last report) | 457.79 k | 523.99 k | 735.12 k | 895.63 k | 457.79 k | 523.99 k |
| Cash remaining | 20.62 k | -45.58 k | -256.71 k | -417.22 k | 20.62 k | -45.58 k |
| Runway (months of cash) | 0.3 | -0.5 | -2.1 | -2.8 | 0.3 | -0.5 |
Institutional ownership, Q1 2022
35.9% owned by funds/institutions
| 13F holders | Current |
|---|---|
| Total holders | 2 |
| Opened positions | 1 |
| Closed positions | 0 |
| Increased positions | 0 |
| Reduced positions | 0 |
| 13F shares | Current |
|---|---|
| Total value | 13.96 mm |
| Total shares | 51.53 mm |
| Total puts | 0.00 |
| Total calls | 0.00 |
| Total put/call ratio | – |
| Largest owners | Shares | Value |
|---|---|---|
| Essetifin SPA | 51.52 mm | $13.96 mm |
| Williams Jones Wealth Management | 10.00 k | $2.00 k |
Recent insider trades
| Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
|---|---|---|---|---|---|---|---|---|---|---|
| 17 May 22 | Mcnay Joseph C | Stock Option Common Stock | Grant | Acquire A | No | No | 0.19 | 290,000 | 55.10 k | 290,000 |
| 17 May 22 | Finkelstein J J | Stock Option Common Stock | Grant | Acquire A | No | No | 0.19 | 600,000 | 114.00 k | 600,000 |
| 17 May 22 | Elsey R Don | Stock Option Common Stock | Grant | Acquire A | No | No | 0.19 | 290,000 | 55.10 k | 290,000 |
| 17 May 22 | Noseda Alessandro | Stock Option Common Stock | Grant | Acquire A | No | No | 0.19 | 240,000 | 45.60 k | 240,000 |
| 17 May 22 | Bove Mauro | Stock Option Common Stock | Grant | Acquire A | No | No | 0.19 | 240,000 | 45.60 k | 240,000 |